Monte Rosa Therapeutics (GLUE) Capital Expenditures (2020 - 2026)

Monte Rosa Therapeutics' Capital Expenditures history runs 7 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 514.47% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.7 million (up 372.34% YoY), while the FY2025 annual figure was $149000.0, up 198.0% from the prior year.
• Capital Expenditures was $1.9 million for Q1 2026 at Monte Rosa Therapeutics, up from -$3.8 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $11.3 million in Q2 2023 to a low of -$17.1 million in Q4 2023.
• Historically, Capital Expenditures has averaged $895000.0 across 5 years, with a median of $1.7 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Capital Expenditures sank 309.72% in 2023, then surged 514.47% in 2026.
• A 5-year view of Capital Expenditures shows it stood at $8.2 million in 2022, then tumbled by 309.72% to -$17.1 million in 2023, then surged by 78.06% to -$3.8 million in 2024, then dropped by 0.77% to -$3.8 million in 2025, then soared by 149.37% to $1.9 million in 2026.
• The last three Capital Expenditures figures came in at $1.9 million (Q1 2026), -$3.8 million (Q4 2025), and $651000.0 (Q3 2025), per Business Quant data.